Canadian clinical-stage psychedelics company Algernon Pharmaceuticals (OTCQB: AGNPF)’s newly created subsidiary Algernon NeuroScience (AGN Neuro) has dosed the first subject in its Phase 1 clinical study of proprietary IV formulation of DMT, AP-188.

The trial is being conducted at the Centre for Human Drug Research in Leiden, the Netherlands.

Renowned psychopharmacologist and Algernon consultant Prof. David Nutt commented that, while “a significant number of promising stroke drugs have failed because they were focused on trying to be neuroprotective of the brain during a stroke,” preclinical data shows that “DMT is promoting neuroplasticity, a key mechanism in recovery once the stroke has occurred, which is a new and exciting approach to …

Full story available on Benzinga.com